Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Clin Breast Cancer. 2021 Dec 2;22(4):308–318. doi: 10.1016/j.clbc.2021.11.012

Figure 4 –

Figure 4 –

DFS according to TIL levels (>20%, 5–20% and <5%) in patients with ADRB2-high (A), and ADRB2-low (B) tumors.

Abbreviations: ADRB2, beta-2 adrenergic receptor gene; DFS, disease-free survival; HR, hazard ratio; TILs, tumor-infiltrating lymphocytes.